Revenue during the quarter plunged 44.30 percent to $0.17 million from $0.31 million in the previous year period.

Operating loss for the quarter was $49.28 million, compared with an operating loss of $24.21 million in the previous year period.

"In 2016 we were saddened by the loss of Dale Schenk, PhD, our friend and former chief executive officer, and a true scientific pioneer," said Gene Kinney, PhD, president and chief executive officer of Prothena. "As a testament to our team’s talent and commitment, our business continued to gain momentum and 2016 was a year of significant progress where we reported positive data for each of our three clinical programs. As our pipeline continues to mature, several key milestones in 2017 and into 2018 keep us on track towards our goal of delivering novel disease modifying therapies to patients. For NEOD001 in patients with AL amyloidosis, we expect to complete enrollment in the PRONTO study during the next several weeks and in the VITAL study during the second quarter. Also in 2017, for PRX002/RG7935, we expect to initiate, with our partners at Roche, a Phase 2 clinical study in patients with Parkinson’s disease. For PRX003 we expect to report full topline results from a Phase 1b multiple ascending dose, proof-of-biology study in patients with psoriasis, and for PRX004 we continue to advance our preclinical work toward the start of a Phase 1 clinical study in patients with ATTR amyloidosis."